Biopure, Others Remain On Long Road With 'Oxygen Therapeutics' Jan. 24, 2005 By Brady Huggett No Comments
Vitex Downsizing By 40 Percent, Raising $20M If Merger Closes Dec. 13, 2004 By Brady Huggett No Comments
Vitex Downsizing By 40 Percent, Raising $20M If Merger Closes Dec. 13, 2004 By Brady Huggett No Comments
Dynavax's Phase II/III HBV Data Supportive; Phase III Trials Next Dec. 10, 2004 By Brady Huggett No Comments
Dynavax's Phase II/III HBV Data Supportive; Phase III Trials Next Dec. 10, 2004 By Brady Huggett No Comments
Preos Data AT ACR Nicks NPS, But Anabolic Market 'Growing' Oct. 25, 2004 By Brady Huggett No Comments
Preos Data AT ACR Nicks NPS, But Anabolic Market 'Growing' Oct. 25, 2004 By Brady Huggett No Comments
After Flu Vaccine Mess, Chiron's Q3 Earnings 'Almost Irrelevant' Oct. 22, 2004 By Brady Huggett No Comments Chiron Corp. released its third-quarter earnings Wednesday, and while those figures were better than expected, the Fluvirin disaster has faded their importance. (BioWorld Today)Read More